BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30269038)

  • 1. Heterogenous treatment for anti-NMDAR encephalitis in children leads to different outcomes 6-12 months after diagnosis.
    Sakpichaisakul K; Patibat L; Wechapinan T; Sri-Udomkajrorn S; Apiwattanakul M; Suwannachote S
    J Neuroimmunol; 2018 Nov; 324():119-125. PubMed ID: 30269038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review.
    Suppiej A; Nosadini M; Zuliani L; Pelizza MF; Toldo I; Bertossi C; Tison T; Zoccarato M; Marson P; Giometto B; Dale RC; Sartori S
    Brain Dev; 2016 Aug; 38(7):613-22. PubMed ID: 26926399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis.
    Wang J; Lin J; Wang M; Meng Z; Zhou D; Li J
    Front Immunol; 2021; 12():774664. PubMed ID: 34975861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
    Titulaer MJ; McCracken L; Gabilondo I; Armangué T; Glaser C; Iizuka T; Honig LS; Benseler SM; Kawachi I; Martinez-Hernandez E; Aguilar E; Gresa-Arribas N; Ryan-Florance N; Torrents A; Saiz A; Rosenfeld MR; Balice-Gordon R; Graus F; Dalmau J
    Lancet Neurol; 2013 Feb; 12(2):157-65. PubMed ID: 23290630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti-NMDAR encephalitis in tertiary care hospitals: A multicenter retrospective/prospective cohort study.
    Pruetarat N; Netbaramee W; Pattharathitikul S; Veeravigrom M
    Brain Dev; 2019 May; 41(5):436-442. PubMed ID: 30639077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong.
    Ho AC; Chan SH; Chan E; Wong SS; Fung ST; Cherk SW; Fung EL; Ma KH; Tsui KW; Yau EK; Wong VC
    Brain Dev; 2018 Jun; 40(6):473-479. PubMed ID: 29599011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    Huang Q; Wu Y; Qin R; Wei X; Ma M
    J Neurol; 2016 Dec; 263(12):2446-2455. PubMed ID: 27632180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review.
    DeSena AD; Noland DK; Matevosyan K; King K; Phillips L; Qureshi SS; Greenberg BM; Graves D
    J Clin Apher; 2015 Aug; 30(4):212-6. PubMed ID: 25664728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy strategy for 35 cases of severe anti-N-methyl-D-aspartate receptor encephalitis].
    Yuan J; Peng B; Guan HZ; Huang Y; Lu Q; Ren HT; Yang XZ; Jiang N; Zhu YC; Cui LY
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(13):1035-9. PubMed ID: 27055797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    Wang Y; Zhang W; Yin J; Lu Q; Yin F; He F; Peng J
    J Neuroimmunol; 2017 Nov; 312():59-65. PubMed ID: 28935354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis.
    Zekeridou A; Karantoni E; Viaccoz A; Ducray F; Gitiaux C; Villega F; Deiva K; Rogemond V; Mathias E; Picard G; Tardieu M; Antoine JC; Delattre JY; Honnorat J
    J Neurol; 2015 Aug; 262(8):1859-66. PubMed ID: 25987208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care.
    de Montmollin E; Demeret S; Brulé N; Conrad M; Dailler F; Lerolle N; Navellou JC; Schwebel C; Alves M; Cour M; Engrand N; Tonnelier JM; Maury E; Ruckly S; Picard G; Rogemond V; Magalhaes É; Sharshar T; Timsit JF; Honnorat J; Sonneville R;
    Am J Respir Crit Care Med; 2017 Feb; 195(4):491-499. PubMed ID: 27552490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis.
    Lee WJ; Lee ST; Shin YW; Lee HS; Shin HR; Kim DY; Kim S; Lim JA; Moon J; Park KI; Kim HS; Chu K; Lee SK
    Neurotherapeutics; 2021 Jan; 18(1):474-487. PubMed ID: 32880854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of anti-NMDAR encephalitis presented hypotensive shock during plasma exchange.
    Miyauchi A; Monden Y; Osaka H; Takahashi Y; Yamagata T
    Brain Dev; 2016 Apr; 38(4):427-30. PubMed ID: 26524986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of pediatric Anti-NMDA receptor encephalitis.
    Shim Y; Kim SY; Kim H; Hwang H; Chae JH; Choi J; Kim KJ; Yum MS; Ko TS; Kim YO; Byeon JH; Lee J; Lee J; Kim JS; Lim BC
    Eur J Paediatr Neurol; 2020 Nov; 29():87-91. PubMed ID: 33046392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    Bartolini L; Muscal E
    J Neurol; 2017 Apr; 264(4):647-653. PubMed ID: 28154970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
    Iizuka T; Kaneko J; Tominaga N; Someko H; Nakamura M; Ishima D; Kitamura E; Masuda R; Oguni E; Yanagisawa T; Kanazawa N; Dalmau J; Nishiyama K
    JAMA Neurol; 2016 Jun; 73(6):706-13. PubMed ID: 27111481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis.
    Pham HP; Daniel-Johnson JA; Stotler BA; Stephens H; Schwartz J
    J Clin Apher; 2011 Dec; 26(6):320-5. PubMed ID: 21898576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.
    Nosadini M; Eyre M; Molteni E; Thomas T; Irani SR; Dalmau J; Dale RC; Lim M; ; Anlar B; Armangue T; Benseler S; Cellucci T; Deiva K; Gallentine W; Gombolay G; Gorman MP; Hacohen Y; Jiang Y; Lim BC; Muscal E; Ndondo A; Neuteboom R; Rostásy K; Sakuma H; Sartori S; Sharma S; Tenembaum SN; Van Mater HA; Wells E; Wickstrom R; Yeshokumar AK
    JAMA Neurol; 2021 Nov; 78(11):1333-1344. PubMed ID: 34542573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of 71 cases of anti-N-methyl-D-aspartate receptor encephalitis in children].
    Wang GL; Yin F; Wang Y; Zhang WX; He F; Yang LF; Wu LW; Peng J
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):125-130. PubMed ID: 30695887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.